Ignite Creation Date:
2024-05-05 @ 9:20 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00864578
Status:
WITHDRAWN
Last Update Posted:
2012-06-06
First Post:
2009-03-17
Brief Title:
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Sponsor:
Sooft Italia
Organization:
Sooft Italia
Study Overview
Official Title:
Effects of the Oral Administration of an Association of Forskolin With Rutin and Vitamins B on Intraocular Pressure IOP in Patients Affected by Primary Open Angle Glaucoma POAG Under Maximun Tolerated Medical Therapy MTMT
Status:
WITHDRAWN
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
loss of interest before enrolment started
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma Several drugs exist on the market that may decrease IOP in glaucomatous patients However some patients cannot reach the target pressure despite a multitherapy with a combination of drugs and are therefore addressed to surgical treatments Forskolin is a natural compound that is a receptor-independent adenyl-cyclase activator that increases intracellular cAMP It has been shown to be able to decrease IOP after topical application by a mechanism that is not used by the other drugs Aim of the present study is to see whether a food supplement containing forskolin KRONEK has any effect on the IOP of POAG patients that cannot reach their target pressure and are therefore on the waiting list for surgical intervention
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| KRONEK-001 | None | None | None |